|Videos|May 25, 2017

Why is May Lyme Disease Awareness Month?

Patricia Smith, President of the Lyme Disease Association, Inc, explains why May is Lyme Disease Awareness Month.

Patricia Smith, President of the Lyme Disease Association, Inc, explains why May is Lyme Disease Awareness Month.

Interview Transcript (slightly modified for readability):

“The Governor of New Jersey just signed a proclamation which declares that in New Jersey, May is [designated as] Lyme Awareness Month. That is consistent with what has happened in many other states, and it used to happen also at the federal level. Our state legislature in New Jersey passed a resolution in 2008 that said every May [will be] Lyme Awareness Month. The reason is because [although] the ticks have been active already, they are a lot more active now [in May].

[Designating May as Lyme Disease Awareness Month] draws attention to the issue and enables groups to put out all kinds of educational information, [as well as] videos, and events to say, ‘This is Lyme Disease, and [these] are tick-borne diseases and we have to know about them.’ We have to understand them because education is the key to understanding how we are going to stop this epidemic that’s sweeping, not just our country, but [also] more than 80 countries.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.